Compile Data Set for Download or QSAR
Report error Found 52 Enz. Inhib. hit(s) with all data for entry = 3524
TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403235BDBM403235(US10329303, Example 34)
Affinity DataEC50:  1nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403225BDBM403225(US10329303, Example 24)
Affinity DataEC50:  1nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403040BDBM403040(US10329303, Example 6)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403239BDBM403239(US10329303, Example 38)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 402876BDBM402876(US10329303, Example 1)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403224BDBM403224(US10329303, Example 23)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403252BDBM403252(US10329303, Example 51)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403184BDBM403184(US10329303, Example 20)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403253BDBM403253(US10329303, Example 52)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403188BDBM403188(US10329303, Example 21)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403218BDBM403218(US10329303, Example 22)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403142BDBM403142(US10329303, Example 15)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403251BDBM403251(US10329303, Example 50)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403246BDBM403246(US10329303, Example 45)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403118BDBM403118(US10329303, Example 14)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403041BDBM403041(US10329303, Example 7)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403093BDBM403093(US10329303, Example 9)
Affinity DataEC50: <20nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403095BDBM403095(US10329303, Example 11)
Affinity DataEC50:  25nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403059BDBM403059(US10329303, Example 8)
Affinity DataEC50:  34nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403229BDBM403229(US10329303, Example 28)
Affinity DataEC50:  40nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403111BDBM403111(US10329303, Example 13)
Affinity DataEC50:  50nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403241BDBM403241(US10329303, Example 40)
Affinity DataEC50:  50nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403182BDBM403182(US10329303, Example 19)
Affinity DataEC50:  70nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403234BDBM403234(US10329303, Example 33)
Affinity DataEC50:  70nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403109BDBM403109(US10329303, Example 12)
Affinity DataEC50:  75nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403236BDBM403236(US10329303, Example 35)
Affinity DataEC50:  80nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403228BDBM403228(US10329303, Example 27)
Affinity DataEC50:  80nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403230BDBM403230(US10329303, Example 29)
Affinity DataEC50:  80nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403240BDBM403240(US10329303, Example 39)
Affinity DataEC50:  90nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403094BDBM403094(US10329303, Example 10)
Affinity DataEC50:  90nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403227BDBM403227(US10329303, Example 26)
Affinity DataEC50:  90nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403237BDBM403237(US10329303, Example 36)
Affinity DataEC50:  100nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403238BDBM403238(US10329303, Example 37)
Affinity DataEC50:  100nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403232BDBM403232(US10329303, Example 31)
Affinity DataEC50:  100nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403158BDBM403158(US10329303, Example 17)
Affinity DataEC50:  100nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 402882BDBM402882(US10329303, Example 2)
Affinity DataEC50:  100nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403025BDBM403025(US10329303, Example 5)
Affinity DataEC50:  160nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 402975BDBM402975(US10329303, Example 4)
Affinity DataEC50:  200nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403245BDBM403245(US10329303, Example 44)
Affinity DataEC50:  200nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403155BDBM403155(US10329303, Example 16)
Affinity DataEC50:  220nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403226BDBM403226(US10329303, Example 25)
Affinity DataEC50:  300nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403244BDBM403244(US10329303, Example 43)
Affinity DataEC50:  500nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403231BDBM403231(US10329303, Example 30)
Affinity DataEC50:  600nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403242BDBM403242(US10329303, Example 41)
Affinity DataEC50:  800nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403233BDBM403233(US10329303, Example 32)
Affinity DataEC50:  900nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403181BDBM403181(US10329303, Example 18)
Affinity DataEC50:  900nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 402974BDBM402974(US10329303, Example 3)
Affinity DataEC50:  5.50E+3nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403248BDBM403248(US10329303, Example 47)
Affinity DataEC50:  5.50E+3nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403249BDBM403249(US10329303, Example 48)
Affinity DataEC50:  5.50E+3nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMalignant T-cell-amplified sequence 1(Human)
The Scripps Research Institute

US Patent
LigandChemical structure of BindingDB Monomer ID 403250BDBM403250(US10329303, Example 49)
Affinity DataEC50:  5.50E+3nMAssay Description:pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

Displayed 1 to 50 (of 52 total ) | Next | Last >>
Jump to: